M.D. Anderson Cancer Center: Thyroid Neoplasms trials

The registry lists 18 Thyroid Neoplasms studies with M.D. Anderson Cancer Center as lead sponsor. 5 are open to participants now and 1 have results posted.

Phase 1 5Phase 2 8No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Nanosecond Pulsed Field Ablation in the Management of T1N0M0 Papillary Thyroid CarcinomaRecruitingNCT07218315Not applicable
• Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before SurgeryRecruitingNCT06959511Phase 2
• Global Real World Data in Patients With Advanced Thyroid Cancer on Standard of Care and Specialized Interventions- Registry of Oncologic Outcomes With Testing and Treatment.RecruitingNCT06507878
• Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME TrialRecruitingNCT04693377Not applicable
• An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer and Other Malignancies of the Head and Neck Undergoing Radiation Therapy and/or Systemic TherapyRecruitingNCT04589624Phase 1
• A Prospective Study Using Implanted Fiducial Markers to Assess Treatment Accuracy and Esophageal Toxicity in Spinal Stereotactic Body Radiation TherapyCompletedNCT01624220Not applicableResults posted
• Radiofrequency Ablation for the Treatment of Benign or Low Risk Thyroid NoduleTerminatedNCT05003856Not applicable
• Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid CancerActive, not recruitingNCT04759911Phase 2
• Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid CancerActive, not recruitingNCT04171622Phase 2
• Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine CancersWithdrawnNCT04106843Phase 2
• Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid TumorsTerminatedNCT03420963Phase 1
• Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid CancerActive, not recruitingNCT03181100Phase 2
• Lenvatinib and Capecitabine in Patients With Advanced MalignanciesWithdrawnNCT02915172Phase 1
• Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal CordActive, not recruitingNCT02713269Phase 2
• Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine CancerCompletedNCT02592356Not applicable
• Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid CancerActive, not recruitingNCT01709292Phase 2
• Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign DiseaseTerminatedNCT01552434Phase 1
• Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid CarcinomaTerminatedNCT00354523Phase 1/2